Biocon Management Guidance Tracker

Management expects core EBITDA margins for Biocon Biologics to recover to mid-thirties as legacy rebate issues normalize and integration completes.

Management reiterated a mid-30s core EBITDA margin target for Biocon Biologics, with current margins depressed by ~5% due to integration-related one-off costs expected to normalize.

Syngene expects operating EBITDA margin to be similar to FY24 levels (~31%).

Gross margins in generics are expected to improve in the second half of FY26, driven by new product launches.

Management expects annualized interest cost savings of approximately ₹300 crore starting FY27, following the retirement of structured debt.

Management reiterated that biosimilar EBITDA margin for the full year FY26 will be in the mid-20s, despite Q3 margin of 28%.

Margins improved to 22% for FY26; management expects further operating leverage as new products ramp up.

Generics segment guided for mid-teen revenue growth for the fiscal year, with better second half due to capacity expansions and new product launches.

Management reaffirmed full-year revenue guidance of $1 billion for Biocon Biologics, driven by market share gains and new product launches.

Generics business expects improved second half performance, with formulations steady at ~INR 400 crore per half and API recovery, but full-year growth revised to low teens/high single digit.

Syngene expects constant currency revenue growth of single-digit to low double-digit in FY25.

Generics business is expected to deliver high single-digit revenue growth for the full year, with H2 significantly stronger than H1.

First generic Liraglutide approved in UK; launch expected in Q3 FY25, contributing to generics recovery.

Biocon Biologics expects to launch biosimilar Ustekinumab in the US in Q4 FY25, pending FDA approval.

Yesintek (biosimilar to Stelara) will launch in the US in February 2025, with a global rollout including Europe.

First GLP-1 generic will launch in the UK in Q4 FY25, followed by EU national launches in Q1 FY26.

Target action date in H2 2025; facility cleared, queries responded; ready to launch immediately upon approval.

Management expects strong double-digit revenue growth for the generics segment for the full fiscal year, driven by multiple product launches including liraglutide in Europe and the U.S.

Syngene's performance in H1 is in line with expectations, and the company is maintaining its annual guidance for FY26.

Management expects continued growth in biosimilars, with new product launches scaling in H2 FY27.

Generics business expected to grow at 17-20% CAGR over the next 4-5 years, driven by peptides, injectables, and fermentation.

Syngene is expected to deliver mid-teen constant currency growth for the full year, supported by strong performance in development and manufacturing services.

Biocon Biologics remains on track to file ustekinumab (Stelara biosimilar) before the end of 2023, with denosumab filing expected by end of next year.

Generics business aims to return to mid-teens growth in FY25, driven by formulations momentum and new peptide revenues, despite current API pricing pressure.

Generics performance expected to build throughout the year with stronger second half, driven by new formulation launches.

Management expects Q2 to be similar to Q1, with a transition to accelerated growth in the second half of FY25, driven by biosimilars traction, new generic launches, and Syngene momentum.

Management expects a transition to accelerated growth in H2, driven by Syngene returning to growth, maintained biosimilars momentum, and generics recovery from new launches.

Generics business targets mid-teens revenue growth over the next two years, driven by peptides, new OSDs, and injectables.

Generics business expected to return to mid-teens growth in FY26, driven by liraglutide and other launches.

Management expects to launch Yesintek (launched), Bevacizumab, Aspart, Aflibercept (US H2 2026), and Denosumab within the next 12-18 months.

Liraglutide U.S. file is under FDA review with a target action date; approval and launch expected during FY26.

Biocon Biologics expects U.S. FDA approval for denosumab before the end of calendar 2025.

Semaglutide will be filed in Q2 FY26 in many emerging markets and Canada, with best-case approval by end of calendar 2026.

Management expects R&D investment for biosimilars to remain in the 7-9% range of segment revenue for FY26.

Generics R&D spend is expected to be in the 8-10% range of segment revenue.

Settlement with originator allows entry; management expects meaningful revenue contribution from H2.

Capital expenditure for biosimilars business guided at $150 million, primarily for Malaysia expansion and insulin capacity ramp-up.

Biologics CapEx of ~$100 million (Malaysia expansion) and generics CapEx of ~$50 million; thereafter largely maintenance CapEx from FY27.

Group capex has moderated from ~$275 million to less than $225 million, and will decline further as Malaysia insulin capacity buildup completes.

Management emphasized continued debt reduction, having repaid $200M of acquisition debt in Q3, with further deleveraging expected from cash flows and other options.

Biocon Biologics expects R&D investments to be in the 8%-9% of revenues range.

Management intends to reduce debt further during FY25, following a $250 million reduction last year, but no specific timeline or amount was provided.

With VAI status for manufacturing sites, management expects expedited FDA review for these biosimilars.

First tranche expected to complete by mid-June 2025; proceeds primarily to meet structured debt obligations from Biocon Biologics investments.

Free cash flow will be prioritized for deleveraging; interest cost savings of ~₹75 Cr per quarter expected.

The acquired Stelis biologics facility is expected to be operational in the second half of FY25, subject to regulatory approvals, adding 20,000L capacity.

Biocon expects to launch ustekinumab (Stelara biosimilar) in the US in the last quarter of FY25, subject to FDA approval and settlement agreements.

The Malaysia insulin drug product capacity expansion is expected to go commercial in FY27, doubling current capacity.